Not Yet RecruitingNot Applicable

Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes

90 participantsStarted 2025-09-01

Plain-language summary

The primary objective of this clinical trial is to evaluate the efficacy and safety of a topical Urtica dioica cataplasm in managing knee pain and functional limitations in athletic children diagnosed with Osgood-Schlatter Disease. Efficacy will be assessed through changes in knee pain using the Visual Analog Scale (VAS) and functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Three groups will be tested: * UDC Group: topical application of Urtica dioica cataplasm * Standard Care Group: oral vitamin D supplementation and physical rest * Placebo Group: topical application of a placebo cataplasm using Beta vulgaris subsp. cicla

Who can participate

Age range7 Years – 15 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy male children between 7 and 15 years of age * Active in regular sports practice (e.g., football) * Clinically confirmed diagnosis of OSD Exclusion Criteria: * Known allergy to Urtica dioica * Presence of dermatological conditions or lesions on the knees * Recent use of anti-inflammatory medications * History of immune or chronic inflammatory diseases * Diagnosis of any other bone disorder

What they're measuring

Pain intensity

Timeframe: At each clinical visit during the intervention period (three times a week during 6 weeks).

Trial details

NCT IDNCT07096037

SponsorFaculty of Medicine, Sousse

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-15

Contact for this trial

Amira Zairi, Pr.

+21698424285 zairi_amira@yahoo.fr

View on ClinicalTrials.gov More Osgood-Schlatter Disease trials